Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Zynex Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Zynex wird ein Gewinn- und Umsatzwachstum von 37.3% bzw. 19.8% pro Jahr prognostiziert, während der Gewinn pro Aktie um 38% pro Jahr wachsen soll.

Wichtige Informationen

37.3%

Wachstumsrate der Gewinne

38.0%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	16.7%
Wachstumsrate der Einnahmen	19.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	10 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Earnings Update: Here's Why Analysts Just Lifted Their Zynex, Inc. (NASDAQ:ZYXI) Price Target To US$19.88

May 03

Earnings Miss: Zynex, Inc. Missed EPS By 33% And Analysts Are Revising Their Forecasts

Mar 03

Recent updates

Earnings Update: Here's Why Analysts Just Lifted Their Zynex, Inc. (NASDAQ:ZYXI) Price Target To US$19.88

May 03

Earnings Miss: Zynex, Inc. Missed EPS By 33% And Analysts Are Revising Their Forecasts

Mar 03

Zynex begins enrollment in blood loss detection trial for CM-1600 monitoring system

Sep 21

These 4 Measures Indicate That Zynex (NASDAQ:ZYXI) Is Using Debt Safely

Aug 02

Zynex Cures The Pain Of Its Shareholders: Q2 Results

Aug 01

Zynex: Upside Looks Well Priced In, Efficiency Headwinds Remain

Jul 25

Is Zynex, Inc. (NASDAQ:ZYXI) Trading At A 46% Discount?

Jul 12

Zynex June and Q2 orders hit all-time high, re-affirms Q2 and FY22 guidance

Jul 11

Is It Time To Consider Buying Zynex, Inc. (NASDAQ:ZYXI)?

Apr 13

Zynex (NASDAQ:ZYXI) Seems To Use Debt Quite Sensibly

Mar 23

Zynex: Letter Indicates UnitedHealthcare Is Terminating Contract - An Undisclosed Loss Accounting For 50%+ EBITDA

Feb 17

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:ZYXI - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	345	43	43	N/A	1
12/31/2025	281	29	26	30	3
12/31/2024	227	16	14	19	3
3/31/2024	189	8	17	18	N/A
12/31/2023	184	10	17	18	N/A
9/30/2023	186	16	16	16	N/A
6/30/2023	177	17	14	15	N/A
3/31/2023	169	17	13	14	N/A
12/31/2022	158	17	13	14	N/A
9/30/2022	150	18	16	17	N/A
6/30/2022	143	20	12	13	N/A
3/31/2022	137	19	14	14	N/A
12/31/2021	130	17	6	7	N/A
9/30/2021	116	10	-3	-2	N/A
6/30/2021	101	5	-7	-7	N/A
3/31/2021	89	5	-6	-5	N/A
12/31/2020	80	9	0	1	N/A
9/30/2020	69	10	4	5	N/A
6/30/2020	60	11	7	7	N/A
3/31/2020	52	10	5	5	N/A
12/31/2019	45	9	6	6	N/A
9/30/2019	41	9	7	7	N/A
6/30/2019	37	10	8	8	N/A
3/31/2019	34	10	9	10	N/A
12/31/2018	32	10	8	9	N/A
9/30/2018	31	10	9	10	N/A
6/30/2018	29	10	9	10	N/A
3/31/2018	27	9	9	9	N/A
12/31/2017	23	7	N/A	8	N/A
9/30/2017	18	4	N/A	5	N/A
6/30/2017	15	3	N/A	3	N/A
3/31/2017	13	1	N/A	1	N/A
12/31/2016	13	0	N/A	2	N/A
9/30/2016	13	-1	N/A	1	N/A
6/30/2016	12	-2	N/A	1	N/A
3/31/2016	12	-2	N/A	1	N/A
12/31/2015	12	-3	N/A	0	N/A
9/30/2015	11	-1	N/A	0	N/A
6/30/2015	13	-1	N/A	0	N/A
3/31/2015	11	-6	N/A	1	N/A
12/31/2014	11	-6	N/A	1	N/A
9/30/2014	12	-11	N/A	1	N/A
6/30/2014	13	-12	N/A	1	N/A
3/31/2014	17	-8	N/A	1	N/A
12/31/2013	22	-7	N/A	0	N/A
9/30/2013	29	-2	N/A	0	N/A
6/30/2013	34	-1	N/A	-1	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ZYXIDas prognostizierte Gewinnwachstum (37.3% pro Jahr) liegt über der Sparquote (2.4%).

Ertrag vs. Markt: ZYXIDie Erträge des Unternehmens (37.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (14.7% pro Jahr).

Hohe Wachstumserträge: ZYXIEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: ZYXIDie Einnahmen des Unternehmens (19.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.4% pro Jahr).

Hohe Wachstumseinnahmen: ZYXIDie Einnahmen des Unternehmens (19.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ZYXI in 3 Jahren voraussichtlich hoch sein wird

Zynex Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Earnings Update: Here's Why Analysts Just Lifted Their Zynex, Inc. (NASDAQ:ZYXI) Price Target To US$19.88

Zynex, Inc. Provides Earnings Guidance for the Second Quarter of 2024 and Reaffirms for the Full Year 2024

Price target increased by 8.1% to US$19.88

Consensus EPS estimates fall by 11%

Earnings Miss: Zynex, Inc. Missed EPS By 33% And Analysts Are Revising Their Forecasts

Zynex, Inc. Provides Earnings Guidance First Quarter and Full Year 2024

Recent updates

Earnings Update: Here's Why Analysts Just Lifted Their Zynex, Inc. (NASDAQ:ZYXI) Price Target To US$19.88

Zynex, Inc. Provides Earnings Guidance for the Second Quarter of 2024 and Reaffirms for the Full Year 2024

Price target increased by 8.1% to US$19.88

First quarter 2024 earnings released: EPS: US$0 (vs US$0.043 in 1Q 2023)

Zynex, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Zynex, Inc., Annual General Meeting, May 16, 2024

Consensus EPS estimates fall by 11%

Earnings Miss: Zynex, Inc. Missed EPS By 33% And Analysts Are Revising Their Forecasts

Full year 2023 earnings: EPS and revenues miss analyst expectations

Zynex, Inc. Provides Earnings Guidance First Quarter and Full Year 2024

Zynex, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Zynex, Inc. Introduces New Products

Zynex, Inc. Receives FDA Clearance for its Next Generation NMES Device

Why Investors Shouldn't Be Surprised By Zynex, Inc.'s (NASDAQ:ZYXI) P/E

Zynex, Inc. Submits FDA Application for Its NMES Device

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $20 million worth of its shares.

Zynex, Inc. Provides Earnings Guidance for Fourth Quarter and Full Year of 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations

Price target decreased by 24% to US$16.50

Investor sentiment deteriorates as stock falls 15%

Zynex, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Now 23% undervalued after recent price drop

Now 22% undervalued after recent price drop

Investor sentiment improves as stock rises 16%

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $10 million worth of its shares.

Now 23% undervalued after recent price drop

Chief Financial Officer recently sold US$170k worth of stock

Chief Financial Officer notifies of intention to sell stock

Investor sentiment deteriorates as stock falls 16%

Is Zynex (NASDAQ:ZYXI) Using Too Much Debt?

Second quarter 2023 earnings: EPS exceeds analyst expectations

Price target increased by 11% to US$24.00

Zynex, Inc. to Report Q2, 2023 Results on Jul 27, 2023

Zynex, Inc. Confirms Earnings Guidance for the Second Quarter of 2023 and Reiterates Earnings Guidance for the Full Year 2023

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $10 million worth of its shares.

Investor sentiment improves as stock rises 30%

Are Investors Undervaluing Zynex, Inc. (NASDAQ:ZYXI) By 43%?

Full year 2022 earnings: EPS exceeds analyst expectations

Investor sentiment deteriorates as stock falls 24%

Should You Be Adding Zynex (NASDAQ:ZYXI) To Your Watchlist Today?

Zynex, Inc. Reaffirms Earnings Guidance for the Fourth Quarter and Full Year 2022

Now 25% undervalued

Insufficient new directors

Chief Financial Officer recently sold US$407k worth of stock

Investor sentiment improved over the past week

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $10 million worth of its shares.

Third quarter 2022 earnings: EPS exceeds analyst expectations

Zynex, Inc. Provides Revenue Guidance for the Fourth Quarter 2022

Zynex, Inc. to Report Q3, 2022 Results on Oct 27, 2022

Zynex, Inc. Re-Iterates Earnings Guidance for the Full Year 2022

Short Squeeze Candidate With Low PEG Ratio: Zynex

Zynex, Inc. Begins Enrollments in Large-Scale Blood Loss Detection Clinical Trial with its Second-Generation Monitoring System, CM-1600

Zynex begins enrollment in blood loss detection trial for CM-1600 monitoring system

Zynex, Inc. Announces First Enrollments in Apheresis Donation Clinical Trial with Second Generation Fluid Monitoring System

These 4 Measures Indicate That Zynex (NASDAQ:ZYXI) Is Using Debt Safely

Zynex Cures The Pain Of Its Shareholders: Q2 Results

Zynex, Inc. Provides Revenue Guidance for the Third Quarter of 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Zynex: Upside Looks Well Priced In, Efficiency Headwinds Remain

Zynex, Inc. to Report Q2, 2022 Results on Jul 28, 2022

Zynex, Inc. Reiterates Revenue Guidance Full Year 2022

Is Zynex, Inc. (NASDAQ:ZYXI) Trading At A 46% Discount?

Zynex June and Q2 orders hit all-time high, re-affirms Q2 and FY22 guidance

Investor sentiment improved over the past week

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $10 million worth of its shares.

First quarter 2022 earnings: EPS misses analyst expectations

Insufficient new directors

Zynex, Inc. to Report Q1, 2022 Results on Apr 28, 2022

Is It Time To Consider Buying Zynex, Inc. (NASDAQ:ZYXI)?